
Trident Lifeline Ltd’s Stake in Trident Mediquip Limited Adjusts Following Private Placement
Trident Lifeline Ltd reported a change in its shareholding in its subsidiary, Trident Mediquip Limited, following a recent Private Placement of equity shares conducted by the subsidiary.The transaction confirms that Trident Mediquip Limited, a subsidiary of Trident Lifeline Ltd, completed the private placement of equity shares to other shareholders. This corporate action has adjusted Trident Lifeline Limited's stake, bringing its holding down to 59.47%.
Profile of Trident Mediquip Limited
Trident Mediquip Limited is a company incorporated under the provisions of the Companies Act, 2013. It operates in the Pharmaceuticals and Chemical Industry and has its registered office in Surat, Gujarat. The company’s primary business line involves Pharmaceuticals.The company's financial details and operational history are as follows:
| Detail | Value |
|---|---|
| CIN | U33309GJ2019PLC110421 |
| Authorized Share Capital | Rs. 10,00,00,000/- |
| Paid-up Share Capital | Rs. 9,86,58,000/- |
| Current Turnover | 21.29 Cr |
| Date of Incorporation | October 19, 2019 |
| Presence | India |
The company has maintained consistent turnover over the last three reported financial years:
| Financial Year | Turnover (Cr) |
|---|---|
| 2022-23 | 28.77 |
| 2023-24 | 20.58 |
| 2024-25 | 21.29 |
Transaction Overview
Trident Lifeline Limited confirmed that since Trident Mediquip Limited is its subsidiary, the transaction constitutes a related party matter. The details confirm that the private placement was undertaken on an arm's length basis.The adjustment in shareholding is reflected in the following percentages:
| Metric | Percentage |
|---|---|
| Pre-holding | 59.77% |
| Post-holding | 59.47% |
Stock Price Movement
As the market closed today, Trident Lifeline Ltd shares settled at ₹249.65, finishing with a gain of 0.06%. Throughout the trading session, the stock moved significantly, carving out a range that stretched from a low of ₹249.30 up to a peak of ₹268.00.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.